BioWorld Asia

March 19, 2003

For $55M, OSI Gets Novantrone U.S. Cancer Rights From Serono

Serono SA signed a licensing agreement with OSI Pharmaceuticals Inc., granting OSI exclusive rights to market and promote Novantrone in the U.S. in its approved oncology indications. (BioWorld International) Read More

OncoGenome Sciences Raises EUR14M For Cancer Diagnostics

New Drugs Could Flow From Bacterial Gene Cluster Variants

UroGene Second Round: EUR12M For Itself, Subsidiary Chrysalon

Riding Smallpox Contracts, Acambis Reports 2002 Profit

EU Worries More Biotechnology Companies Could Quit Europe

Entomed, Naeja Enter Two-Way Cancer, Infectious Diseases Deal

Potential OGS Buyers, CAT, Celltech, Jockey For Position

CellFactors Seeking £3.5M To Advance, Partner Skeletex

Products, Fundamentals Find Investor Favor In Down Market

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...